Indeed, the use of a specific inhibitor targeting GLS leads to an inhibition of MYC-induced B-cell lymphoma and MYC-induced hepatocarcinoma (83), while, GDH inhibition results in lower α-KG levels and high ROS production, resulting in hindering of cancer cell proliferation and tumor progression (94). This evidence concerns the gene GLUD1 and cancer.